marketcaparena

Burning Rock Biotech Ltd

BNR · Figures in Chinese yuan

About Burning Rock Biotech

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

brbiotech.com ↗

Employees
667
Business address
GUANGZHOU, GUANGDONG
Listed
Nasdaq · BNR

Price

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$17.63
+$8.70 (+97.40%)past year
Market cap
$191M
At close
Sep 28, 2026

Share price vs index

Burning Rock Biotech's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Burning Rock Biotech is ahead, orange while it is behind. The values at the end are each one's change over the range.

Revenue mix

Revenue by segment

FY25
Full year
Revenue reported by each segment. The figure at the top of each column is total revenue. Where a company reports eliminations between segments, the columns show segment revenue before them; hover a column for the eliminations and the reported total. Switch to % to see each segment's share.

Revenue by product

FY25
Full year
Revenue reported for each product. The figure at the top of each column is the total of the products shown. Switch to % to see each product's share.

Segment growth

FY25
Year
Each segment's revenue in the chosen period against the same period a year earlier (YoY), so seasonal swings cancel out, or against the quarter before (QoQ). A year is always compared with the year before. Hover or tap a line to bring it forward.

Product growth

FY25
Year
Each product's revenue in the chosen period against the same period a year earlier (YoY), so seasonal swings cancel out, or against the quarter before (QoQ). A year is always compared with the year before. Hover or tap a line to bring it forward.

Revenue by geography

FY24
Full year
Reported countries and regions in the chosen year or quarter. Known regions use standard geographic footprints. Hover shows the reported region total, never an allocation to individual countries. Ambiguous remainders are not mapped.

Geography growth

FY24
Year
Each country's or region's revenue in the chosen period against the same period a year earlier (YoY), so seasonal swings cancel out, or against the quarter before (QoQ). A year is always compared with the year before. Hover or tap a line to bring it forward.

Top geographies

FY24
Full year
Reported countries and regions in the chosen year or quarter, largest first, in the map's colours. The share of the disclosed geography shows only where the reported parts add up.

Income statement

Revenue, gross profit and net income

FY25
Full year
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Income statement

FY25
Full year
How revenue becomes net income in the chosen year or quarter. Solid bars are totals; hatched bars are the costs taken off between them.
TotalAddedSubtracted

Operating leverage

FY25
Full year
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.

Cash flow

Operating and free cash flow

FY25
Full year
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Cash flow statement

FY25
Full year
The reported movements behind the change in cash in the chosen year or quarter. Solid bars are totals; hatched bars are what was added or taken off between them.
TotalAddedSubtracted

Capital allocation

FY25
Full year
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Stock-based compensation

FY25
Full year
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation% of revenue

Balance sheet

Assets, liabilities and equity

Q4 25
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

Net cash

Q4 25
Full year
Quarter
Cash and short-term investments minus total debt at each quarter end. Below zero, the company owes more than it holds.
Net cashNet debt

War chest

Q4 25
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.